Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer
The Prep-02/JSAP05 trial results showed that neoadjuvant chemotherapy with gemcitabine plus S-1 significantly extends survival compared with upfront surgery in patients with resectable PDAC.
Authors
- Ippei Matsumoto (ORCID: https://orcid.org/0000-0003-3965-3693)
- Suefumi Aosasa (ORCID: https://orcid.org/0000-0002-8167-6306)
- Hideyuki Yoshitomi (ORCID: https://orcid.org/0000-0003-2911-8056)
- Hirochika Toyama (ORCID: https://orcid.org/0000-0003-0360-8460)
- Masayuki Sho
- Fuyuhiko Motoi (ORCID: https://orcid.org/0000-0001-7601-8395)
- Tsutomu Fujii (ORCID: https://orcid.org/0000-0003-0625-1911)
- Hideki Ueno (ORCID: https://orcid.org/0000-0002-8600-1199)
- Michiaki Unno (ORCID: https://orcid.org/0000-0002-2145-6416)
- Shinichiro Takahashi (ORCID: https://orcid.org/0000-0002-4828-3965)
- Yutaka Matsuyama (ORCID: https://orcid.org/0000-0003-2009-6831)
- Sohei Satoi
- Tomoo Kosuge
- Hirofumi Shirakawa
- Keita Wada
Institutions
- Yamagata University (JP)
- Kansai Medical University (JP)
- Chiba University (JP)
- Tohoku University (JP)
- Tochigi Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
- National Defense Medical College (JP)
- Nagoya University (JP)
- Nara Medical University (JP)
- Kobe University (JP)
- The University of Tokyo (JP)
- Teikyo University (JP)
- Kindai University (JP)
Publication Details
- Journal
- Annals of Surgery
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1097/sla.0000000000006730
- Citations
- 39
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 40.77